Behaegel J, Ní Dhubhghaill S, Koppen C, Zakaria N
Faculty of Medicine and Health Sciences, Department of Ophthalmology, Visual Optics and Visual Rehabilitation, University of Antwerp, Campus Drie Eiken, T building, T4-Ophthalmology, Universiteitsplein 1, 2610 Antwerp, Belgium.
Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, CCRG-Oogheelkunde, Wilrijkstraat 10, 2650 Edegem, Belgium.
Stem Cells Int. 2017;2017:6978253. doi: 10.1155/2017/6978253. Epub 2017 Mar 30.
Ex vivo cultivated limbal stem cell transplantation is a promising technique for the treatment of limbal stem cell deficiency. While the results of the clinical trials have been extensively reported since the introduction of the technique in 1997, little has been reported regarding the potential health risks associated with production processes and transplantation techniques. Culture procedures require the use of animal and/or human-derived products, which carry the potential of introducing toxic or infectious agents through contamination with known or unknown additives. Protocols vary widely, and the risks depend on the local institutional methods. Good manufacturing practice and xeno-free culture protocols could reduce potential health risks but are not yet a common practice worldwide. In this review, we focus on the safety of both autologous- and allogeneic-cultivated limbal stem cell transplantation, with respect to culture processes, surgical approaches, and postoperative strategies.
体外培养的角膜缘干细胞移植是一种治疗角膜缘干细胞缺乏症的有前景的技术。自1997年该技术问世以来,临床试验结果已有广泛报道,但关于生产过程和移植技术相关的潜在健康风险报道较少。培养程序需要使用动物和/或人源产品,这有可能通过已知或未知添加剂的污染引入有毒或传染性病原体。方案差异很大,风险取决于当地机构的方法。良好生产规范和无动物源培养方案可以降低潜在健康风险,但在全球范围内尚未成为普遍做法。在本综述中,我们聚焦于自体和异体培养的角膜缘干细胞移植在培养过程、手术方法及术后策略方面的安全性。